{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:13:23Z","timestamp":1789535603322,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T00:00:00Z","timestamp":1571097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"KAKENHI","award":["25430103"],"award-info":[{"award-number":["25430103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00262-019-02413-w","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T11:26:43Z","timestamp":1571138803000},"page":"1769-1778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Contribution of Fc\u03b3 receptor IIB to creating a suppressive tumor microenvironment in a mouse model"],"prefix":"10.1007","volume":"68","author":[{"given":"Yuki","family":"Kasahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Shirota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Umegaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,15]]},"reference":[{"key":"2413_CR1","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014\u20131022","journal-title":"Nat Immunol"},{"key":"2413_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri1936","volume":"6","author":"L Zitvogel","year":"2006","unstructured":"Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715\u2013727","journal-title":"Nat Rev Immunol"},{"key":"2413_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science (New York, N.Y.) 331:1565\u20131570","journal-title":"Science (New York, N.Y.)"},{"key":"2413_CR4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1078\/0171-9335-00346","volume":"82","author":"LC van Kempen","year":"2003","unstructured":"van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82:539\u2013548","journal-title":"Eur J Cell Biol"},{"key":"2413_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","volume":"348","author":"JA Joyce","year":"2015","unstructured":"Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, N.Y.) 348:74\u201380","journal-title":"Science (New York, N.Y.)"},{"key":"2413_CR6","first-page":"4095","volume":"63","author":"Z Qin","year":"2003","unstructured":"Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63:4095\u20134100","journal-title":"Cancer Res"},{"key":"2413_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423\u20131437","journal-title":"Nat Med"},{"key":"2413_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","volume":"8","author":"F Nimmerjahn","year":"2008","unstructured":"Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34\u201347","journal-title":"Nat Rev Immunol"},{"key":"2413_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/ni.2939","volume":"15","author":"A Pincetic","year":"2014","unstructured":"Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707\u2013716","journal-title":"Nat Immunol"},{"key":"2413_CR10","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2326-6066.CIR-15-0120","volume":"3","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo DJ, Ravetch JV (2015) Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 3:704\u2013713","journal-title":"Cancer Immunol Res"},{"key":"2413_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","volume":"35","author":"S Bournazos","year":"2017","unstructured":"Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV (2017) Signaling by antibodies: recent progress. Annu Rev Immunol 35:285\u2013311","journal-title":"Annu Rev Immunol"},{"key":"2413_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2005.11.010","volume":"24","author":"F Nimmerjahn","year":"2006","unstructured":"Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19\u201328","journal-title":"Immunity"},{"key":"2413_CR13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1084\/jem.20020165","volume":"195","author":"S Bolland","year":"2002","unstructured":"Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV (2002) Genetic modifiers of systemic lupus erythematosus in Fc gamma RIIB(\u2212\/\u2212) mice. J Exp Med 195:1167\u20131174","journal-title":"J Exp Med"},{"key":"2413_CR14","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1084\/jem.189.1.179","volume":"189","author":"R Clynes","year":"1999","unstructured":"Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189:179\u2013185","journal-title":"J Exp Med"},{"key":"2413_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s002510050641","volume":"51","author":"Y Jiang","year":"2000","unstructured":"Jiang Y, Hirose S, Abe M, Sanokawa-Akakura R, Ohtsuji M, Mi X, Li N, Xiu Y, Zhang D, Shirai J, Hamano Y, Fujii H, Shirai T (2000) Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51:429\u2013435","journal-title":"Immunogenetics"},{"key":"2413_CR16","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.4049\/jimmunol.180.8.5670","volume":"180","author":"TL McGaha","year":"2008","unstructured":"McGaha TL, Karlsson MC, Ravetch JV (2008) FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl\u2013MpJ mice. J Immunol 180:5670\u20135679","journal-title":"J Immunol"},{"key":"2413_CR17","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/379346a0","volume":"379","author":"T Takai","year":"1996","unstructured":"Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346\u2013349","journal-title":"Nature"},{"key":"2413_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1084\/jem.189.1.187","volume":"189","author":"T Yuasa","year":"1999","unstructured":"Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T (1999) Deletion of fc gamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189:187\u2013194","journal-title":"J Exp Med"},{"key":"2413_CR19","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.4049\/jimmunol.1201063","volume":"190","author":"N Kobayashi","year":"2013","unstructured":"Kobayashi N, Hong C, Klinman DM, Shirota H (2013) Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J Immunol 190:1882\u20131889","journal-title":"J Immunol"},{"key":"2413_CR20","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.4049\/jimmunol.1101304","volume":"188","author":"Y Shirota","year":"2012","unstructured":"Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592\u20131599","journal-title":"J Immunol"},{"key":"2413_CR21","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00262-017-2043-6","volume":"66","author":"SE Ito","year":"2017","unstructured":"Ito SE, Shirota H, Kasahara Y, Saijo K, Ishioka C (2017) IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother CII 66:1485\u20131496","journal-title":"Cancer Immunol Immunother CII"},{"key":"2413_CR22","doi-asserted-by":"crossref","first-page":"982","DOI":"10.4049\/jimmunol.134.2.982","volume":"134","author":"MK Warren","year":"1985","unstructured":"Warren MK, Vogel SN (1985) Bone marrow-derived macrophages: development and regulation of differentiation markers by colony-stimulating factor and interferons. J Immunol 134:982\u2013989","journal-title":"J Immunol"},{"key":"2413_CR23","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.2741\/4545","volume":"22","author":"M Benvenuto","year":"2017","unstructured":"Benvenuto M, Mattera R, Masuelli L, Tresoldi I, Giganti MG, Frajese GV, Manzari V, Modesti A, Bei R (2017) The crossroads between cancer immunity and autoimmunity: antibodies to self antigens. Front Biosci (Landmark Ed) 22:1289\u20131329","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2413_CR24","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00262-009-0733-4","volume":"58","author":"M Reuschenbach","year":"2009","unstructured":"Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother CII 58:1535\u20131544","journal-title":"Cancer Immunol Immunother CII"},{"key":"2413_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.autrev.2016.01.017","volume":"15","author":"P Zaenker","year":"2016","unstructured":"Zaenker P, Gray ES, Ziman MR (2016) Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 15:477\u2013483","journal-title":"Autoimmun Rev"},{"key":"2413_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-16-0113","volume":"5","author":"H Shirota","year":"2017","unstructured":"Shirota H, Klinman DM, Ito SE, Ito H, Kubo M, Ishioka C (2017) IL4 from T follicular helper cells downregulates antitumor immunity. Cancer Immunol Res 5:61\u201371","journal-title":"Cancer Immunol Res"},{"key":"2413_CR27","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/nm.4200","volume":"22","author":"KD Moynihan","year":"2016","unstructured":"Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ (2016) Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22:1402\u20131410","journal-title":"Nat Med"},{"key":"2413_CR28","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.1073\/pnas.1209067111","volume":"111","author":"OM Pearce","year":"2014","unstructured":"Pearce OM, Laubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A (2014) Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci USA 111:5998\u20136003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2413_CR29","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1158\/0008-5472.CAN-15-1330","volume":"75","author":"N Gul","year":"2015","unstructured":"Gul N, van Egmond M (2015) Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res 75:5008\u20135013","journal-title":"Cancer Res"},{"key":"2413_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","volume":"28","author":"R Dahan","year":"2015","unstructured":"Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 axis. Cancer Cell 28:285\u2013295","journal-title":"Cancer Cell"},{"key":"2413_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","volume":"27","author":"A Roghanian","year":"2015","unstructured":"Roghanian A, Teige I, Martensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendeus B, Cragg MS (2015) Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell 27:473\u2013488","journal-title":"Cancer Cell"},{"key":"2413_CR32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nri856","volume":"2","author":"T Takai","year":"2002","unstructured":"Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2:580\u2013592","journal-title":"Nat Rev Immunol"},{"key":"2413_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.4049\/jimmunol.1103703","volume":"189","author":"N van Montfoort","year":"2012","unstructured":"van Montfoort N, t Hoen PA, Mangsbo SM, Camps MG, Boross P, Melief CJ, Ossendorp F, Verbeek JS (2012) Fcgamma receptor IIB strongly regulates Fc gamma receptor-facilitated T cell activation by dendritic cells. J Immunol 189:92\u2013101","journal-title":"J Immunol"},{"key":"2413_CR34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrc1929","volume":"6","author":"AJ Muller","year":"2006","unstructured":"Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6:613\u2013625","journal-title":"Nat Rev Cancer"},{"key":"2413_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086","journal-title":"Cancer Discov"},{"key":"2413_CR36","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.4049\/jimmunol.1301430","volume":"19","author":"EL Williams","year":"2013","unstructured":"Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ (2013) Immunotherapy targeting inhibitory Fc\u03b3 receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 19:4130\u20134140","journal-title":"J Immunol"},{"key":"2413_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/1074-7613(95)90134-5","volume":"3","author":"M Daeron","year":"1995","unstructured":"Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3:635\u2013646","journal-title":"Immunity"},{"key":"2413_CR38","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1126\/science.1118948","volume":"310","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (New York, N.Y.) 310:1510\u20131512","journal-title":"Science (New York, N.Y.)"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02413-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T17:58:19Z","timestamp":1695319099000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02413-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,15]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2413"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02413-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,15]]},"assertion":[{"value":"24 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was approved by the Institutional Committee for the Use and Care of Laboratory Animals of Tohoku University. Animal research approval number: 2017-171-1. All in vivo experiments were conducted in strict accordance with good animal practice and complied with ethics committee guidelines of Tohoku University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no conflicts of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"C57Bl\/6 mice were obtained from Japan SLC (Hamamatsu, Japan). Fc\u03b3RIIB KO mice were provided by Takai et al. (Department of Experimental Immunology, Tohoku University, Sendai, Japan).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal source"}},{"value":"The following cell lines were purchased from American Type Culture collection (Manassas, VA): E.G7, LLC, TC-1 and B16 melanoma. No cell line authentication was necessary.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell line authentication"}}]}}